Earnings Feed
Start Free
Envoy Medical, Inc.·4

Feb 17, 4:45 PM ET

BRYNELSEN CHARLES 4

4 · Envoy Medical, Inc. · Filed Feb 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Envoy Medical (COCH) Director Charles Brynelsen Buys 1,000,000 Shares

What Happened Charles Brynelsen, a director of Envoy Medical, reported purchases on 2026-02-12. He purchased 1,000,000 shares of Class A common stock at $0.40 per share for $400,000. The Form 4 also shows two derivative acquisitions totaling 1,600,000 units recorded at $0.00 (600,000 and 1,000,000 respectively); these are described in footnotes as warrants/options with specific exercise and expiration conditions.

Key Details

  • Transaction date: 2026-02-12; Form 4 filed 2026-02-17 (filed 5 days after the reported transactions).
  • Cash purchase: 1,000,000 shares @ $0.40 = $400,000.
  • Derivatives: 600,000 and 1,000,000 derivative securities reported as acquired at $0.00 (see footnotes for terms).
  • Shares owned after transaction: Not disclosed in the provided filing details.
  • Notable footnotes:
    • F1: Certain options vesting schedule (46,875 vested 10/15/2023; 15,625 vest pro rata monthly over 36 months).
    • F2: Some instruments exercisable only upon shareholder approval to issue the underlying Class A shares.
    • F3/F4: Series A-1 and A-2 warrants have expirations tied to time limits and FDA milestones (PMA submission or approval).
  • Filing timeliness: Appears late relative to the transaction date (filed 5 days after the trades); late Form 4s reduce near-term transparency.

Context

  • The $400K cash purchase is a direct buy of common stock (often viewed as a stronger signal than gifts or routine sales, but it is not proof of future performance).
  • The zero-price derivative entries indicate acquisition of rights (warrants/options) rather than an immediate cash exercise; footnotes show those rights have conditions (shareholder approval, FDA milestone-related expirations).
  • No indication in the provided data that any shares were immediately sold (no cashless exercise noted).

Insider Transaction Report

Form 4
Period: 2026-02-12
Envoy Medical, Inc.COCH
BRYNELSEN CHARLES
Director
Transactions
  • Purchase

    Class A Common Stock

    2026-02-12$0.40/sh+1,000,000$400,000→ 1,050,000 total
  • Purchase

    Warrant (right to buy)

    [F2][F3]
    2026-02-12+600,000→ 600,000 total
    Exercise: $0.40→ Class A Common Stock (600,000 underlying)
  • Purchase

    Warrant (right to buy)

    [F2][F4]
    2026-02-12+1,000,000→ 1,000,000 total
    Exercise: $0.40→ Class A Common Stock (1,000,000 underlying)
Holdings

  • Stock Option (right to buy)

    [F1]
    Exercise: $2.40Exp: 2033-10-15→ Class A Common Stock (62,500 underlying)
    62,500

  • Stock Option (right to buy)

    Exercise: $0.81From: 2026-05-01Exp: 2035-12-03→ Class A Common Stock (62,500 underlying)
    62,500
Footnotes (4)
  • [F1]Options to purchase 46,875 shares vest on 10/15/2023, and the remaining 15,625 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
  • [F2]Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
  • [F3]The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
  • [F4]The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.
Signature
/s/ Andrew Nick as Attorney-in-Fact for Charles Brynelsen pursuant to Power of Attorney previously filed.|2026-02-16

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES